Commissioner of Central Excise Belapur Vs Jindal Drugs Ltd. (Supreme Court of India)
The Supreme Court recently addressed a crucial question regarding the Central Excise Act: Does labelling or re-labelling containers constitute ‘manufacture’ for CENVAT credit eligibility? This question arose in the case of Commissioner of Central Excise Belapur vs Jindal Drugs Ltd., which had significant implications for taxation and regulatory compliance.
The crux of the matter revolved around the interpretation of Note 3 to Chapter 18 of the Central Excise Tariff Act. This note specifies activities that qualify as ‘manufacture,’ including labelling or re-labelling of containers. The Court examined the legislative intent behind this provision, noting a crucial amendment made in 2008.
Pre-amendment, the note required a composite process of labelling/re-labelling and repacking to constitute ‘manufacture.’ However, post-amendment, the amendment replaced ‘and’ with ‘or,’ expanding the scope. Now, labelling or re-labelling of containers alone qualifies as ‘manufacture,’ distinct from repacking.
The Court carefully analyzed the language of the statute and legislative history, concluding that labelling constitutes an independent manufacturing activity.
In light of the above analysis, the Supreme Court affirmed the decision of the Customs, Excise, and Service Tax Appellate Tribunal (CESTAT), holding that labelling qualifies as ‘manufacture’ for CENVAT credit eligibility.
